Skip to main content
Premium Trial:

Request an Annual Quote

Prenetics to Take Majority Stake in ACT Genomics

NEW YORK — Prenetics Global said on Friday that it will acquire a majority stake in Hong Kong-based precision oncology firm ACT Genomics.

In exchange for the undisclosed stake, Prenetics, also headquartered in Hong Kong, will issue 19.9 million shares of its ordinary stock to ACT and pay $20 million in cash. Additional terms were not disclosed.

ACT provides a range of genomic testing services for major solid tumor types to help guide clinicians' treatment decisions. It also offers biomarker discovery and company diagnostic development services to academic and industry partners. The company — which maintains operations in Hong Kong, Taiwan, Japan, Singapore, Thailand, and the UK — merged with lung cancer diagnostic developer Sanomics last year.

"With the addition of ACT's technologies, capabilities, and team, Prenetics will be well-positioned to accelerate the utilization of genetic information throughout a cancer patient's journey," Prenetics Cofounder and CEO Danny Yeung said in a statement. "Starting from risk profiling and diagnostic testing, moving to therapy optimization, monitoring, and recurrence surveillance, Prenetics will be able to deliver the information needed to enable best-in-class personalized cancer care."

Prenetics said that ACT is expected to contribute between $25 million and $30 million in revenues next year.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.